Breaking News

Lantheus and POINT Biopharma Enter Strategic Collaboration and Exclusive License Agreement

Expands Lantheus’ portfolio with license of exclusive worldwide rights, excluding certain territories, to two late-stage therapeutic agents.

Author Image

By: Charlie Sternberg

Associate Editor

Lantheus Holdings Inc., a company committed to improving patient outcomes through diagnostics, radiotherapeutics and artificial intelligence solutions, and POINT Biopharma Global Inc., a company accelerating discovery, development and global access to life-changing radiopharmaceuticals, have signed a set of strategic collaboration agreements in which Lantheus will license exclusive worldwide rights to POINT’s PNT2002 and PNT2003 product candidates.   Upon consummation of the agreements, in exc...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters